Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 14, 2009, Pages 3973-3976

  Yamamoto, Takeshi ^a   Shibata, Norio ^a   Sukeguchi, Daisuke ^a   Takashima, Masayuki ^a   Nakamura, Shuichi ^a   Toru, Takeshi ^a   Matsunaga, Nozomu ^b   Hara, Hideaki ^b   Tanaka, Motohiro ^c   Obata, Tohru ^c   Sasaki, Takuma ^c  

^a NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Asymmetric synthesis; Metabolites; Thalidomide

Indexed keywords

4 HYDROXYPHTHALIC ANHYDRIDE; 5 HYDROXYTHALIDOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG METABOLITE; HEXAMETHYLDISILAZANE; PHTHALIC ANHYDRIDE; SILANE DERIVATIVE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN A; ZINC BROMIDE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL REACTION; COCULTURE; DRUG HYDROLYSIS; DRUG SCREENING; DRUG SYNTHESIS; ENANTIOSELECTIVITY; ENDOTHELIUM CELL; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMIDATION; PH; RACEMIZATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN-ION CONCENTRATION; STEREOISOMERISM; THALIDOMIDE;

EID: 67649651961     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.108     Document Type: Article

References (26)

1. Hashimoto Y. Arch. Pharm. 341 (2008) 536
2. Blaschke G., Kraft H.P., Fickentscher K., and Kohler F. Arzneim.-Forsch. 29 (1979) 1640
3. Schmahl H.J., Nau H., and Neubert D. Arch. Toxicol. 62 (1988) 200
4. Knoche B., and Blaschke G. J. Chromatogr., A 666 (1994) 235
5. Nishimura K., Hashimoto Y., and Iwasaki S. Chem. Pharm. Bull. 42 (1994) 1157
6. Boylen J.B., Horne H.H., and Johnson W.J. Can. J. Biochem. Physiol. 42 (1964) 35
7. Marks M.G., Shi J., Fry M.O., Xiao Z., Trzyna M., Pokala V., Ihnat M.A., and Li P.-K. Biol. Pharm. Bull. 25 (2002) 597
8. Inatsuki S., Noguchi T., Miyachi H., Oda S., Iguchi T., Kizaki M., Hashimoto Y., and Kobayashi H. Bioorg. Med. Chem. Lett. 15 (2005) 321
9. Noguchi T., Shinji C., Kobayashi H., Makishima M., Miyachi H., and Hashimoto Y. Biol. Pharm. Bull. 28 (2005) 563
10. Noguchi T., Miyachi H., Katayama R., Naito M., and Hashimoto Y. Bioorg. Med. Chem. Lett. 15 (2005) 3212
11. Noguchi T., Fujimoto H., Sano H., Miyajima A., Miyachi H., and Hashimoto Y. Bioorg. Med. Chem. Lett. 15 (2005) 5509
12. Nakamura T., Noguchi T., Kobayashi H., Miyachi H., and Hashimoto Y. Chem. Pharm. Bull. 54 (2006) 1709
13. Lepper E.R., Smith N.F., Cox M.C., Scripture C.D., and Figg W.D. Curr. Drug Metab. 7 (2006) 677
14. Yamamoto T., Shibata N., Takashima M., Nakamura S., Toru T., Matsunaga N., and Hara H. Org. Biomol. Chem. 6 (2008) 1540
15. Takeuchi Y., Shiragami T., Kimura K., Suzuki E., and Shibata N. Org. Lett. 1 (1999) 1571
16. Suzuki E., and Shibata N. Enantiomer 6 (2001) 275
17. Shibata N., Yamamoto T., and Toru T. In: Eguchi S. (Ed). Top. Heterocycl. Chem. Vol. 8 (2007), Springer, Berlin, Heidelberg 73-97
18. Reddy P.Y., Kondo S., Toru T., and Ueno Y. J. Org. Chem. 62 (1997) 2652
19. Kita Y., Haruta J., Fujii T., Segawa J., and Tamura Y. Synthesis (1981) 451
20. Meyring M., Müehlbacher J., Messer K., Kastner-Pustet N., Bringmann G., Mannschreck A., and Blaschke G. Anal. Chem. 74 (2002) 3726
21. Stephens T.D. Teratology 38 (1988) 229
22. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4082
23. Parman T., Wiley M.J., and Wells P.G. Nat. Med. 5 (1999) 582
24. Izuta H., Chikaraishi Y., Shimazawa M., Mishima S., and Hara H. Evid. Based Complement. Altern. Med. (2007) 10.1093/ecam/nem152
25. Chikaraishi Y., Shimazawa M., and Hara H. Exp. Eye Res. 84 (2007) 529
26. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., and Mitchell J.B. Cancer Res. 47 (1987) 943